Friday, 16 October 2026European Markets

REC SILICON Stock Over 11% Up At Session Start On Tuesday

Loading stream...

(VIANEWS) - Shares of REC SILICON (Oslo Børs Benchmark Index_GI: RECSI.OL) jumped by a staggering 11.85% to kr17.56 at 10:39 EST on Tuesday, after two sequential sessions in a row of losses. Oslo Børs Benchmark Index_GI is jumping 1.32% to kr1,180.69, following the last session's upward trend. This seems, as yet, an all-around up trend exchanging session today.

REC SILICON's last close was kr15.70, 37.7% under its 52-week high of kr25.20.

About REC SILICON

REC Silicon ASA, together with its subsidiaries, produces and sells silicon materials for the solar and electronics industries worldwide. It offers various solar grade polysilicon for solar applications, including granular polysilicon, Siemens rod sections, chunks, chips, and fines. The company also provides electronic grade polysilicon comprising TearDrop, as-grown Siemens rods, rod sections, chunks, and chips for use in Czochralski monocrystalline ingot/wafer manufacturing for the semiconductor industry, as well as other electronic market segments, such as optics and microelectromechanical systems; and float zone polysilicon. In addition, it offers silicon gases consisting of silane, dichlorosilane, monochlorosilane, disilane, and polysilanes. The company was formerly known as Renewable Energy Corporation ASA and changed its name to REC Silicon ASA in October 2013. REC Silicon ASA was founded in 1996 and is headquartered in Lysaker, Norway.

Earnings Per Share

As for profitability, REC SILICON has a trailing twelve months EPS of kr-1.33.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -185.49%.

Volume

Today's last reported volume for REC SILICON is 3985936 which is 44.29% below its average volume of 7155650.

More news about REC SILICON (RECSI.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com